Technology & Innovation

SHERIDAN, WYOMING - December 8, 2025 - The U.S. Food and Drug Administration is preparing a fundamental shift in its evidentiary standards for new drugs, with Commissioner Marty Makary signaling that a single pivotal trial could soon be sufficient for approval-a move that has roiled internal leadership, unsettled some regulators and analysts, and triggered immediate recalculations in biopharma portfolio models.

From Two Pivotal Trials to One: A Structural Break

SHERIDAN, WYOMING - December 8, 2025 - Denali Therapeutics is facing another regulatory setback after the U.S. Food and Drug Administration (FDA) placed a clinical hold on DNL952, its enzyme replacement candidate for Pompe disease, citing preclinical hypersensitivity signals and demanding protocol changes before the company can start Phase I studies.

FDA Flags Hypersensitivity Risk Before First Human Dosing

The clinical hold, disclosed in an SEC filing, stems from "hypersensitivity reactions" observed in mouse models. While the agency has not required additional non-clinical studies, it is insisting on a more conservative first-in-human plan. Denali has been asked to lower the proposed starting dose for DNL952 and implement "revised inclusion criteria, adjusted stopping rules and unspecified safety monitoring commitments" before the program can proceed.

SHERIDAN, WYOMING - December 8, 2025 - Praxis Precision Medicines has doubled down on its neurology strategy with back-to-back updates: a Phase II win for its sodium current blocker relutrigine in rare developmental and epileptic encephalopathies (DEE) and a "successful" pre-NDA meeting for its essential tremor candidate ulixacaltamide, positioning the Boston biotech as a potential new commercial player in both ultra-rare epilepsy and movement disorders.

Relutrigine Study Stopped Early for Efficacy in DEE

Praxis has halted its mid-stage EMBOLD trial of relutrigine early, after an independent data monitoring board recommended the study "stop the study early for efficacy." The Phase II EMBOLD study is evaluating relutrigine in patients with DEE linked to SCN8A and SCN2A mutations, a small but highly underserved genetic epilepsy population with limited therapeutic options and high unmet medical need.

SHERIDAN, WYOMING - December 8, 2025 - Days after Johnson & Johnson reported a mid-stage failure for its anti-tau antibody posdinemab, Eisai is using the Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference to argue that tau is still a viable target-if drug designers hit the right part of the protein-while investors and scientists pivot their attention to inflammation and vascular pathways.

Anti-tau Setbacks Raise the Bar for New Entrants

Tau-directed drugs have been among the most high-profile disappointments in Alzheimer's disease (AD) R&D. J&J's recent miss with posdinemab follows last year's Phase II failure of UCB's bepranemab and Eli Lilly's inability to replicate its amyloid success with the anti-tau candidate LY3372689. Collectively, these readouts have fed a narrative that tau may be an intractable or poorly understood target for disease modification.

SHERIDAN, WYOMING - December 8, 2025 - SprintRay's acquisition of the EnvisionTEC dental product portfolio marks a strategic step in the consolidation of the dental 3D printing market, expanding its materials ecosystem, reinforcing supply resilience and giving both SprintRay and EnvisionTEC users clearer long-term pathways in digital production.

What Changes for SprintRay Customers: More Materials, Same Workflow

For existing SprintRay practices and labs, the immediate impact is about breadth rather than disruption. The EnvisionTEC dental portfolio brings additional validated resin formulations that SprintRay is adapting for its own printers, which means customers gain more material options without having to invest in new hardware.

SHERIDAN, WYOMING - December 8, 2025 - Chairside 3D printing has moved from conference buzzword to everyday reality in U.S. dental practices, and SprintRay is positioning its ecosystem as a way for clinics to bring production in-house, compress treatment timelines, and turn same-day crowns into a strategic differentiator rather than a marketing slogan.

From Lab Dependency to In-Practice Production

At its core, "chairside" simply means producing the restoration in your own practice while the patient is still in your care, instead of sending cases to an external lab and waiting one to two weeks. Clinically, the workflow is familiar-examination, preparation, design and cementation remain the same-but the fabrication step moves from a third party you can't control to equipment in your operatory that you can.

SHERIDAN, WYOMING - December 8, 2025 - Heidelberger Druckmaschinen AG (HEIDELBERG) has reached a major milestone with the delivery of its 1,000th Speedmaster CX 104 press, a 14-unit specialty configuration bound for the fast-growing Chinese packaging printer Hoifu Group, underscoring strong demand for high-performance, value-optimized presses in the premium packaging market.

Global Bestseller Targets High-End Packaging Growth in China

The Speedmaster CX 104 has become the bestseller in HEIDELBERG's portfolio thanks to its attractive price-performance ratio and broad suitability for commercial and packaging applications. The landmark 1,000th unit will be installed at Hoifu Group's new site in Yancheng, where it will run as part of an end-to-end, Prinect-based workflow.

SHERIDAN, WYOMING - December 5, 2025 - Stellantis Pro One is using Solutrans 2025 in Lyon to underline its leadership in Europe's light commercial vehicle (LCV) market, combining a strong electric line-up, factory-integrated CustomFit conversions, V2G pilots and renewable fuel demonstrations to help craftsmen, SMEs and large fleets decarbonize without compromising capability.

Electric and Custom-Built Vans for Every Professional Use Case

On its Solutrans stand, Stellantis Pro One presents a broad mix of electric and combustion-powered vans configured through its CustomFit program, designed to address different trades and duty cycles from city logistics to specialist services. The display underlines that electrification and tailored conversions are now core to the Stellantis business model rather than niche options.

Key vehicles on show include:

SHERIDAN, WYOMING - December 5, 2025 - Stellantis is preparing a leadership handover at the top of its global motorsport operations, appointing seasoned engineer and team principal Olivier Jansonnie as Head of Stellantis Motorsport from January 31, 2026, as long-time motorsport chief Jean-Marc Finot retires after nearly four decades shaping performance programs across multiple brands.

Leadership transition at Stellantis Motorsport from 2026

From early 2026, Olivier Jansonnie will assume responsibility for Stellantis Motorsport, reporting to Emanuele Cappellano, Head of Enlarged Europe, European Brands and Stellantis Pro One. The transition will be managed jointly with outgoing leader Jean-Marc Finot to ensure continuity across factory programs, customer racing and high-performance road car initiatives.

SHERIDAN, WYOMING - December 5, 2025 - Stellantis is launching the HVO Aurora project as a practical way for European light commercial vehicle (LCV) fleets to certify the real-world use of renewable diesel, turning low-carbon fuel consumption into traceable data that supports decarbonization strategies and day-to-day operations.

HVO Aurora tracks real-world use of renewable diesel

HVO Aurora is built around Hydrotreated Vegetable Oil (HVO), a renewable fuel produced from waste streams such as used cooking oil and animal fats. By design, it targets a key question for fleet operators: how to prove that vehicles are actually running on low-carbon fuel in daily use, not just on paper.